0.45
+0.0301(+7.17%)
Currency In USD
| Previous Close | 0.42 |
| Open | 0.42 |
| Day High | 0.48 |
| Day Low | 0.42 |
| 52-Week High | 3.89 |
| 52-Week Low | 0.41 |
| Volume | 1.48M |
| Average Volume | 655,100 |
| Market Cap | 18.85M |
| PE | -1.25 |
| EPS | -0.36 |
| Moving Average 50 Days | 0.56 |
| Moving Average 200 Days | 0.97 |
| Change | 0.03 |
If you invested $1000 in FibroBiologics, Inc. Common Stock (FBLG) since IPO date, it would be worth $25.71 as of October 16, 2025 at a share price of $0.45. Whereas If you bought $1000 worth of FibroBiologics, Inc. Common Stock (FBLG) shares 6 months ago, it would be worth $412.84 as of October 16, 2025 at a share price of $0.45.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
FibroBiologics to Present at the 2025 ThinkEquity Conference
GlobeNewswire Inc.
Oct 14, 2025 12:30 PM GMT
HOUSTON, Oct. 14, 2025 (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (Nasdaq: FBLG) (“FibroBiologics”), a clinical-stage biotechnology company with 270+ patents issued and pending with a focus on the development of therapeutics and potential cures for c
FibroBiologics to Present at 2025 Cell & Gene Meeting on the Mesa
GlobeNewswire Inc.
Sep 23, 2025 12:30 PM GMT
HOUSTON, Sept. 23, 2025 (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (Nasdaq: FBLG) (“FibroBiologics”), a clinical-stage biotechnology company with 270+ patents issued and pending with a focus on the development of therapeutics and potential cures for
FibroBiologics Leadership Authors Opinion Editorial Highlighting Fibroblast Cells' Therapeutic Advantages Over Traditional Stem Cell Therapies
GlobeNewswire Inc.
Sep 12, 2025 12:30 PM GMT
HOUSTON, Sept. 12, 2025 (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (Nasdaq: FBLG) (“FibroBiologics”), a clinical-stage biotechnology company with 270+ patents issued and pending with a focus on the development of therapeutics and potential cures for